Latest Breaking News On - Kirsten gruis - Page 1 : comparemela.com

FDA removes hold on investigational new drug application for ischemic stroke therapy

The FDA has removed the clinical hold on the investigational new drug application for the phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke, DiaMedica Therapeutics announced in a press release.“We are pleased that the FDA has fully lifted the clinical hold,” DiaMedica President and CEO Rick Pauls, MBA, said in the release. “DM199 represents a novel approach to treating

Rick paulsKirsten gruisHeather bieleDiamedica therapeuticsMedica president

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaUnited statesRick paulsKirsten gruisPaul papiScott kellenDrug administrationExchange commissionCorporate communicationsDiamedica therapeutics incMedica therapeuticsChief medicalFast track designationSecurities litigation reform actDiamedica therapeutics

DiaMedica Therapeutics Inc (DMAC) Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke

DiaMedica Therapeutics Inc (DMAC) Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Kirsten gruisRick paulsDiamedica therapeutics incDrug administrationDiamedica therapeuticsChief medical

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2023 Financial Results

Conference Call and Webcast May 16 at 8:00 am Eastern Time / 7:00 am Central Time Company Completed In-Use Study, Results Support Proposed ReMEDy2 IV Dose Revision Company Completed a Phase 1C. | May 15, 2023

United statesSouth koreaRick paulsKirsten gruisDiamedica therapeutics incDrug administrationResearch associates groupExchange commissionDiamedica therapeuticsDaylight timeAcute ischemic strokeClinical holdChief executiveChief medicalChief businessMedica management

DiaMedica Therapeutics Inc (NASDAQ:DMAC) Q4 2022 Earnings Call Transcript

Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics ReMEDy2 Update Conference Call.

Tanya lewisKirsten gruisScott kellenDominic cundariAlexander nowakJulie davesAlex nowakThomas flatenRick paulsDiamedica therapeutics incCraig hallum capital groupClinical development operationsHealth photoDiamedica therapeuticsCall transcript marchInvestor relations